全球子宫肌瘤栓塞设备市场 – 行业趋势及 2029 年预测

全球子宫肌瘤栓塞装置市场分析及规模

近年来，子宫肌瘤栓塞术 (UFE) 因其微创技术而在全球得到广泛应用。该技术结合使用实时 X 射线（称为荧光透视）来引导栓塞剂输送到子宫和肌瘤。接受 UFE 治疗的女性中约 90% 的肌瘤相关症状得到显著或完全缓解。

• 2021 年全球子宫肌瘤栓塞设备市场价值为 50.1 亿美元，预计到 2029 年将达到 70.8 亿美元，在 2022-2029 年预测期内的复合年增长率为 4.40%。由于人们对该技术的认知度很高，“微创治疗”在相应市场中占据最大的治疗模式。

全球子宫肌瘤栓塞装置市场定义

子宫肌瘤栓塞术（UFE）是一种微创治疗，广泛应用于治疗子宫肌瘤。该手术称为子宫动脉栓塞术（UAE），用于治疗前置胎盘、骨盆动静脉畸形和胎盘植入等其他并发症。

报告范围和市场细分

Uterine Fibroid Embolization Devices Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:

• Prevalence of Uterine Fibroids

The rise in the prevalence of uterine fibroids among women across the acts as one of the major factors driving the growth of uterine fibroid embolization devices market.

• Preference for Minimally Invasive Surgery

The increase in the preference for minimally invasive surgery owing to the advantages, such as smaller incisions decrease post-operative pain and speedy recovery, accelerate the market growth.

• Increase in Funds

The surge in funding from private and government organizations for development of healthcare sector and research centers further influence the market.

Opportunities

Furthermore, advancements in the procedure and devices devices extend profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, rise in healthcare awareness among the patients will further expand the market.

Restraints/Challenges Global Uterine Fibroid Embolization Devices Market

On the other hand, high cost of medical devices and ongoing healthcare reforms are expected to obstruct market growth. Also, stringent regulations are projected to challenge the uterine fibroid embolization devices market in the forecast period of 2022-2029.

This uterine fibroid embolization devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on uterine fibroid embolization devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 Impact on Uterine Fibroid Embolization Devices Market

COVID-19 had a negative impact on the uterine fibroid embolization devices market owing to the decline in elective surgeries. Hospital access was restricted to non-essential care, and O&P clinics were temporarily closed during the pandemic. The implementation of social distancing, lockdown of the population and limited access to clinics greatly affected the market. The slow-down in patient flow and referrals, and decline in trauma and workplace injuries also impacted the market growth. However, market will resume its growth in the post-pandemic due to the easing in restrictions that were imposed earlier.

Recent Development

• Karl Storz has launched Tele Pack+, a compact endoscopy system in March’2020. The system is a transportable video system that assists in merging all of the key components, such as light source, display and camera control unit together required for diagnosis and treatment.
• Gynesonics, developed Sonata System in July’2020. The system is transcervical fibroid ablation system that makes use of radiofrequency energy for treating symptomatic uterine fibroids. The system detects and then target a single fibroid with a combination of radiofrequency and ultrasound.

Global Uterine Fibroid Embolization Devices Market Scope and Market Size

The uterine fibroid embolization devices market is segmented on the basis of technology and mode of treatment. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• Surgical Techniques
• Laparoscopic Techniques
• Ablation Techniques
• Embolization Techniques

Based on technology, uterine fibroid embolization devices market is segmented into surgical techniques, laparoscopic techniques, ablation techniques and embolization techniques. Surgical techniques have been further segmented into hysterectomy and myomectomy. Laparoscopic Techniques have been further segmented into laparoscopic myomectomy and myolysis. Ablation Techniques have been further segmented into microwave ablation, hydrothermal ablation, cryoablation, ultrasound ablation and other ablation techniques. Ultrasound ablation is segmented into high-intensity focused ultrasound (HIFU) and MRI-guided focused ultrasound (MRGFUS).

Mode of Treatment

• Invasive Treatment
• Minimally Invasive Treatment
• Non-Invasive Treatment

Uterine fibroid embolization devices market has also been segmented based on the mode of treatment into invasive treatment, minimally invasive treatment and non-invasive treatment.

Uterine Fibroid Embolization Devices Market Regional Analysis/Insights

The uterine fibroid embolization devices market is analysed and market size insights and trends are provided by country, technology and mode of treatment as referenced above.

The countries covered in the uterine fibroid embolization devices market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the uterine fibroid embolization devices market because of the presence of well-established healthcare facilities within the region.

Asia-Pacific (APAC) is expected to witness significant growth during the forecast period of 2022 to 2029 due to the large patient base and unmet needs regarding the fibroids diagnosis and treatment in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The uterine fibroid embolization devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for uterine fibroid embolization devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the uterine fibroid embolization devices market. The data is available for historic period 2010-2020.

Competitive Landscape and Uterine Fibroid Embolization Devices Market Share Analysis

The uterine fibroid embolization devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to uterine fibroid embolization devices market.

Some of the major players operating in the uterine fibroid embolization devices market are

• 波士顿科学公司 (美国)
• Merit Medical Systems（美国）
• BioSpace（美国）
• Hologic, Inc.（美国）
• 库克（英国）
• Ferring BV（瑞士）
• Smith+Nephew（英国）
• CooperSurgical, Inc.（美国）
• 宾夕法尼亚州安泰保险公司 (Aetna Better Health of Pennsylvania)（美国）
• Ethicon US, LLC（美国）
• 奥林巴斯美国公司（美国）
• 史赛克（美国）

研究方法：全球子宫肌瘤栓塞设备市场

数据收集和基准年分析是使用具有大样本量的数据收集模块进行的。市场数据使用市场统计和连贯模型进行分析和估计。市场份额分析和关键趋势分析也是市场报告中的主要成功因素。如需了解更多信息，请请求分析师致电或下拉询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请咨询我们的行业专家 https://www.databridgemarketresearch.com/zh/speak-to-analyst/?dbmr=global-uterine-fibroid-embolization-devices-market

SKU-52635